Qlaris Bio

Qlaris Bio is a clinical-stage biotechnology company on a mission to preserve vision and prevent blindness by developing first-in-class therapies for unmet needs in ophthalmology. The company's lead candidate, QLS-111, is a novel vasodilatory topical ATP-sensitive potassium channel modulator designed to reduce intraocular pressure by targeting episcleral venous pressure and improving ocular perfusion. Originally discovered at Mayo Clinic, QLS-111 was developed into a preservative-free eye-drop formulation and demonstrated sustained intraocular pressure reduction with a favorable safety profile in Phase 2 clinical trials (Osprey and Apteryx). The company is headquartered in Dedham, Massachusetts and is backed by leading life sciences investors.